Results 261 to 270 of about 11,695,622 (343)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Measurement of variables: data quality control

open access: bronze, 1981
F. D. Johnstone   +3 more
openalex   +1 more source

Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf   +10 more
wiley   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Reasons for over-reporting of routine immunization administrative data in the Democratic Republic of Congo: a mixed cross-sectional study to determine explanatory factors for poor data quality. [PDF]

open access: yesBMC Public Health
Ngo-Bebe D   +10 more
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

open access: yesMolecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy